Journal article
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
F Bovis, T Kalincik, F Lublin, G Cutter, C Malpas, D Horakova, EK Havrdova, M Trojano, A Prat, M Girard, P Duquette, M Onofrj, A Lugaresi, G Izquierdo, S Eichau, F Patti, M Terzi, P Grammond, R Bergamaschi, P Sola Show all
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
Abstract
OBJECTIVE: To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. METHODS: Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. RESULTS: The overall ARR ratio of GA to IFN-β-1a in the Com..
View full abstractGrants
Awarded by National Center for Advancing Translational Sciences
Funding Acknowledgements
This study was funded by the MSBase Foundation Fellowship. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen, Novartis Pharma, Bayer Schering, Sanofi-Aventis, and BioCSL. This research was supported by the Italian Ministry of Education, University and Research grant PRIN 2017-20178S4EK9. The CombiRx study was funded by NIH/NINDS grant 2U01 NS45719.